Luigi Mangione prosecutors violating his health privacy rights, defense says
"The District Attorney has subpoenaed Mr Mangione's health insurer, and, if their account is to be believed, they partially reviewed confidential, private, protected documents that the District Attorney readily admits are protected by the Health Insurance Portability and Accountability Act. There is no question that the District Attorney has no right to possess or review these documents," the filing said.
MORE: Prosecutors trying to 'bias' the public against Luigi Mangione, defense says
Mangione has pleaded not guilty to murdering UnitedHealthcare chief Brian Thompson on a Midtown street last December. Mangione was not covered by UnitedHealthcare.
Instead, prosecutors have said he wanted to send a message about corporate greed.
His attorneys are now seeking access to information from prosecutors and from Mangione's insurer, Aetna, arguing the subpoena was improper.
"There is no question that the People have violated Mr Mangione's rights under HIPPA by possessing and reviewing the subpoenaed documents. However, the violation goes far beyond this. The violation also involves the intentional and knowing violating of his doctor-patient privilege," the defense said.
MORE: Prosecutors detail how Luigi Mangione allegedly surveilled CEO: 'Checks every box'
The district attorney's office said it will formally respond in court papers.
However, prosecutors said they requested limited information from Aetna and Aetna sent them additional materials in error. Prosecutors said they deleted the materials as soon as they became aware of them and brought it to the attention of both the defense and the court.
The error was compounded by defense counsel resending to prosecutors the very same items prosecutors had already deleted, a source familiar with the subpoena said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
10 minutes ago
- Yahoo
1 Killed in Shooting at University of New Mexico Dorm Building, Suspect in Custody
Students were allowed to return to their dorms, but police remain at the scene A suspect is reportedly in custody after a shooting at the University of New Mexico left one person dead and another injured. On Friday, July 25, UNM informed students that the Albuquerque school was still part of 'an active crime scene on the central corridor of the central campus' following a shelter-in-place issued earlier in the day. 'Evacuation is not mandatory. Dorm students will be able to eat in La Posada and return to their dorm rooms. Please avoid the crime scene shown in the attached image and follow the directions of officers on scene,' the college said in a final emergency update shared to their website at 4:14 p.m. local time. U.S. Marshals in Los Lunas arrested the suspect that afternoon, KOB 4 reported. Neither the suspect nor the two victims were identified. The UNM Police Department responded to a report of gunshots at the Casas del Rio student housing complex that morning, according to the outlet. The shooting took place around 3:00 a.m. local time Friday morning, KRQE added, citing a Lobo Alert. However, students in the Gila building said they heard about 'four or five shots' just before midnight and sheltered in place, KOB 4 reported. The UNM Police Department did not immediately respond to PEOPLE's request for comment. 'I just heard like three pops, three loud pops, and then, uh, we thought it was like gunshots or something, so then we checked out the window and then, like, we just seen like random people running around,' Jubilee Tasi, a freshman from Seattle told KRQE. 'We heard another popping, and then after that, we were just confused on what was going on, so we just called it a night, and then I went to sleep.' The student said they'd been watching a movie with friends at the time of the shooting, and also said they hadn't witnessed any other disturbances since moving in on June 13. 'What happened last night is just crazy, cause I mean, I'm still trying to get used to the environment over here, so for that to happen it's just kinda crazy,' Tasi said. President Garnett Stokes shared a message to the school's social media channels saying 'law enforcement confirmed that multiple shots were fired in the early morning in our Casas del Rio student housing.' 'The shooting resulted in the death of one individual and the injury of another, who is currently being cared for at a local hospital. The identities of both the deceased and the injured individual have not yet been released,' Stokes continued in the lengthy post, which was one of several updates. Want to keep up with the latest crime coverage? Sign up for for breaking crime news, ongoing trial coverage and details of intriguing unsolved cases. School officials urged students and staff to 'Continue to monitor your UNM email, text messages, and LoboGuardian for real-time updates.' The university also said multiple law enforcement agencies were present and actively investigating. Read the original article on People
Yahoo
10 minutes ago
- Yahoo
Elevance Health, Inc. (ELV) Downgrades 2025 Earnings Amid Rising Medical Costs
We recently compiled a list of Elevance Health, Inc. stands third on our list among the most undervalued healthcare stocks. Elevance Health, Inc. (NYSE:ELV) is a major U.S. healthcare company, known for its insurance brands Anthem and WellPoint, and its growing Carelon health services arm. It serves around 45.6 million medical plan members and is recognized for integrating technology and value-based care to improve healthcare delivery. The company is facing increased healthcare utilization and rising medical costs, especially in the ACA and Medicaid segments. This has led to a downgrade in full-year 2025 earnings. A 'market-wide morbidity shift' is evident, with new ACA enrollees using emergency services at nearly double the rate of commercial members, and Medicaid patients showing higher acuity due to redeterminations. Amid these challenges, some investors see Elevance Health, Inc. (NYSE:ELV) as one of the most undervalued stocks in the healthcare sector, given its long-term positioning and strategic adjustments. The company expects a surge in elective procedures by Q4 2025 as members act ahead of expiring tax credits in 2026 that could raise their out-of-pocket costs. To address these pressures, the business is ramping up AI-driven tools for risk detection, care coordination, and operational efficiency. It's also expanding value-based care contracts, particularly in behavioral health and oncology, with over one-third of benefit expenses tied to risk-sharing models. The company is adjusting pricing strategies for ACA plans and advocating for Medicaid access amid potential regulatory changes. A healthcare professional discussing a treatment plan with a patient in an outpatient clinic. Though total membership fell by 212,000 in Q2 due to Medicaid attrition, the Medicare Advantage segment continues to grow. Elevance Health, Inc. (NYSE:ELV) is prioritizing long-term financial stability over aggressive member growth as it navigates rising costs, shifting regulations, and post-pandemic care patterns. While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
10 minutes ago
- Yahoo
Vertex Pharmaceuticals Incorporated (VRTX) Launches JOURNAVX, First Non-Opioid Acute Pain Treatment
We recently compiled a list of Vertex Pharmaceuticals Incorporated stands second on our list and has recently launched the first non opioid acute pain treatment. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), a global biotech firm based in Boston, is known for developing innovative treatments for serious diseases like cystic fibrosis, sickle cell disease, and beta thalassemia. The company is recognized for its strong pipeline targeting unmet medical needs. In July 2025, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) launched JOURNAVX (suzetrigine), a first-in-class, non-opioid treatment for moderate-to-severe acute pain. JOURNAVX, an oral NaV1.8 pain signal inhibitor, was named a 2025 Breakthroughs Innovation Celebration winner by Premier, Inc. It represents the first new class of pain medicine in decades and offers a safer alternative to opioids by directly targeting pain pathways without addiction risks. This launch marks a major advancement in pain management, aligning with public health efforts to reduce opioid use. JOURNAVX is especially relevant for acute pain scenarios such as post-surgical recovery and injury care. A closeup of pills in a pharmacy, representing the high quality medications of the company. Beyond acute pain, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) continues to expand its reach. Its next-gen cystic fibrosis therapy, ALYFTREK, received approval from the European Commission in July 2025, strengthening its global leadership in this area. The company is also advancing gene-editing therapies like CASGEVY for sickle cell and beta thalassemia, and is developing treatments for kidney disease, type 1 diabetes, and rare genetic disorders. While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
